Floatz logo

Modified Vaccinia Virus Ankara Vaccine Expressing P53

Renal Cell Carcinoma

City of Hope Medical CentervaccinePhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

297 Active assets in the Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Modified Vaccinia Virus Ankara Vaccine Expressing P53 is also rated in:

ovarian carcinomaDormant
B
Indicative ·
60 / 100
View asset →
primary peritoneal carcinomaDormant
B
Indicative ·
60 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →